Literature DB >> 34094686

Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin.

Francesca Ricci1, Alessandro Corbelli2, Roberta Affatato1,3, Rosaria Chilà1,4, Michela Chiappa1, Laura Brunelli5, Robert Fruscio6, Roberta Pastorelli5, Fabio Fiordaliso2, Giovanna Damia1.   

Abstract

Mitochondria have attracted attention in cancer research as organelles associated with tumor development and response to therapy. We recently reported acquisition of resistance to cisplatin (DDP) associated with a metabolic rewiring in ovarian cancer patient-derived xenografts (PDXs) models. DDP-resistant PDXs models were obtained mimicking the clinical setting, treating mice bearing sensitive-DDP tumors with multiple cycles of DDP until the development of resistance. To further characterize the metabolic rewiring, the present study focused on tumor mitochondria. We analysed by transmission electron microscopy the mitochondria structure in two models of DDP-resistant and the corresponding DDP-sensitive PDXs and evaluated tumor mDNA content, the expression of genes and proteins involved in mitochondria functionality, and mitochondria fitness-related processes, such as autophagy. We observed a decrease in the number of mitochondria paralleled by an increased volume in DDP-resistant versus DDP-sensitive PDXs. DDP-resistant PDXs presented a higher percentage of damaged mitochondria, in particular of type 2 (concave-shape), and type 3 (cristolysis) damage. We found no difference in the mDNA content, and the expression of genes involved in mitochondrial biogenesis was similar between the sensitive and resistant PDXs. An upregulation of some genes involved in mitochondrial fitness in DDP-R versus DDP-S PDXs was observed. At protein level, no difference in the expression of proteins involved in mitochondrial function and biogenesis, and in autophagy/mitophagy was found. We here reported that the acquisition of DDP resistance is associated with morphological alterations in mitochondria, even if we couldn't find any dysregulation in the studied genes/proteins that could explain the observed differences. AJCR
Copyright © 2021.

Entities:  

Keywords:  Mitochondria; platinum resistance and ovarian carcinoma

Year:  2021        PMID: 34094686      PMCID: PMC8167697     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  48 in total

1.  A mitochondrial switch promotes tumor metastasis.

Authors:  Paolo E Porporato; Valéry L Payen; Jhudit Pérez-Escuredo; Christophe J De Saedeleer; Pierre Danhier; Tamara Copetti; Suveera Dhup; Morgane Tardy; Thibaut Vazeille; Caroline Bouzin; Olivier Feron; Carine Michiels; Bernard Gallez; Pierre Sonveaux
Journal:  Cell Rep       Date:  2014-07-24       Impact factor: 9.423

Review 2.  Mitochondrial mutations in cancer.

Authors:  M Brandon; P Baldi; D C Wallace
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

Review 3.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

Review 4.  Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.

Authors:  Belinda van Zyl; Denise Tang; Nikola A Bowden
Journal:  Endocr Relat Cancer       Date:  2018-02-27       Impact factor: 5.678

Review 5.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors:  David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

6.  Functionally and morphologically damaged mitochondria observed in auditory cells under senescence-inducing stress.

Authors:  Teru Kamogashira; Ken Hayashi; Chisato Fujimoto; Shinichi Iwasaki; Tatsuya Yamasoba
Journal:  NPJ Aging Mech Dis       Date:  2017-01-25

7.  Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Authors:  K Yu; B Chen; D Aran; J Charalel; C Yau; D M Wolf; L J van 't Veer; A J Butte; T Goldstein; M Sirota
Journal:  Nat Commun       Date:  2019-08-08       Impact factor: 14.919

Review 8.  Defects in mitochondrial metabolism and cancer.

Authors:  Edoardo Gaude; Christian Frezza
Journal:  Cancer Metab       Date:  2014-07-17

9.  Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Authors:  Marco Sciacovelli; Emanuel Gonçalves; Timothy Isaac Johnson; Vincent Roberto Zecchini; Ana Sofia Henriques da Costa; Edoardo Gaude; Alizee Vercauteren Drubbel; Sebastian Julian Theobald; Sandra Riekje Abbo; Maxine Gia Binh Tran; Vinothini Rajeeve; Simone Cardaci; Sarah Foster; Haiyang Yun; Pedro Cutillas; Anne Warren; Vincent Gnanapragasam; Eyal Gottlieb; Kristian Franze; Brian Huntly; Eamonn Richard Maher; Patrick Henry Maxwell; Julio Saez-Rodriguez; Christian Frezza
Journal:  Nature       Date:  2016-08-31       Impact factor: 49.962

Review 10.  Three-dimensional electron microscopy techniques for unravelling mitochondrial dysfunction in heart failure and identification of new pharmacological targets.

Authors:  Hussam M Daghistani; Bodour S Rajab; Ashraf Kitmitto
Journal:  Br J Pharmacol       Date:  2018-10-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.